Aggressive prostate cancer phenotype and genome-wide association studies: where are we now?

• Type: Another Publication in an International Scientific Journal
• Date: 2020

Authors

Pinto, AR (Author) Other; Silva, J (Author) Other; Pinto, R (Author) Other; Rui Medeiros (Author) ICBAS

Journal

Title: Pharmacogenomics

Vol. 21

Pages: 487-503

ISSN: 1462-2416

Publisher: ASHLEY PUBLICATIONS LTD

Indexing

ISI Web of Knowledge - 4 Citations

Scopus - 4 Citations

Other information

Authenticus ID: P-00S-60B

DOI: 10.2217/pgs-2019-0123

Abstract (EN): The majority of prostate cancer (PCa) is indolent, however, a percentage of patients are initially diagnosed with metastatic disease, for which there is a worse prognosis. There is a lack of biomarkers to identify men at greater risk for developing aggressive PCa. Genome-wide association studies (GWAS) scan the genome to search associations of SNPs with specific traits, like cancer. To date, eight GWAS have resulted in the reporting of 16 SNPs associated with aggressive PCa (p < 5.00 x 10(-2)). Still, validation studies need to be conducted to confirm the obtained results as GWAS can generate false-positive results. Furthermore, post-GWAS studies provide a better understanding of the functional consequences.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 17